Recent news on Eprosartan Mesylate

Research and Markets: Fenofibrate is Solvay Pharmaceuticals ...  -  Jan 12, 2007
PharmaLive.com (press release),Marinol (dronabinol) and Serc (betahistine); the influenza vaccine, Influvac; the pancreatic enzyme, Creon; and Teveten (eprosartan mesylate) for



Buyout buzz lifts Dishman Pharma 6%  May 12, 2006
...the firm had announced successful completion of US FDA inspection for its facility located at Bavla in Ahmedabad, to manufacture Eprosartan Mesylate, an anti ... - Business Standard

Dishman successfully completes US FDA inspection  May 5, 2006
...that it has successfully completed US FDA inspection for its facility located at Bavla, which is a 100% EOU, to manufacture Eprosartan Mesylate, an anti hyper ... - Moneycontrol.com

Dishman completes USFDA inspection for anti hyper-tension drug  May 5, 2006
The facility, a 100 per cent export oriented unit, manufactures 'Eprosartan Mesylate', which would be supplied to global major Solvay Pharmaceuticals, BV ... - Zee News

Dishman Pharma Completes US FDA Inspection For Its Bayla Unit  May 5, 2006
The Unit which is a 100% EOU, to manufacture Eprosartan Mesylate, an anti hypertension drug, to be supplied to Solvay Pharmaceuticals, BV, a fortune 500 Company ... - Trading Markets

Dishman Pharma to supply more to Solvay  May 5, 2006
Dishman said it would supply 90 tonnes of eprosartan mesylate to Solvay in the current financial year, compared with 60 tonnes in 2005/06. ... - Sify

Bombay Stocks Edge Higher  May 5, 2006
The company has completed US FDA inspection for one of its facility to make Eprosartan Mesylate, an anti hyper-tension drug, to be supplied to Solvay ... - TheStreet.com

INTERVIEW - Dishman sees revenue boost from Solvay order - MD  May 5, 2006
The company would supply 90 tonnes of eprosartan mesylate to Solvay in the current financial year, compared with 60 tonnes in 2005/06, Managing Director JR ... - Reuters India

Wrap Up: Sensex gains 314 points  May 6, 2006
The company has completed US FDA inspection for its facility located at, Bavla, which is a 100% EOU, to manufacture Eprosartan Mesylate, an anti-hypertension ... - Myiris.com



Dishman to expand EM capacity to 7.2mt  Jan 12, 2006
Dishman Pharmaceuticals plans to increase installed capacity of its Eprosartan Mesylate (EM) plant from 6. MT to 7.2 MT per month to meet the future demand of ... - Business Standard

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional